Explore this article's sources with AI
Follow PeptideMethods on Google
DIAL2 risk after semaglutide
A two-year cohort tracked DIAL2-predicted risk after semaglutide, empagliflozin, or both. It did not measure cardiovascular events.
Why we wrote this. The study reports predicted risk trajectories, not cardiovascular outcomes. We separate the model's results from claims it cannot support.
In this article (6 sections)
A 2026 retrospective cohort study followed 332 adults without prior cardiovascular disease after they started oral semaglutide, empagliflozin, or both medicines. Several measured risk factors improved over 24 months, but the proportion classified as high risk by the DIAL2 calculator stayed near 24%. The study tracked calculated risk, not heart attacks, strokes, or cardiovascular deaths.[1] Readers looking for background on the GLP-1 medicine can start with our semaglutide guide.
What the DIAL-STEP study measured
The cohort included 139 people who initiated semaglutide, 106 who initiated empagliflozin, and 87 who initiated the combination. The researchers reviewed changes recorded over two years. Their main endpoint was the share of participants in an investigator-defined high DIAL2 category, meaning a calculated one-year cardiovascular risk of at least 3%. They also examined the calculator's continuous percentage estimate.[1]
DIAL2 is a prediction tool. It combines patient information and measured risk factors to estimate a future probability. Repeating the calculation can show how an estimate moves as age and clinical measurements change. It does not count events that occurred, and a lower calculated percentage is not proof that a medicine prevented an event. A DIAL2 estimate should therefore remain separate from observed cardiovascular outcomes.[1] Our semaglutide evidence overview covers the medicine beyond this risk-model analysis.
Measured risk factors improved over two years
Among participants with paired measurements, average HbA1c fell by 1.13 percentage points over 24 months. Average systolic blood pressure fell by 7.64 mmHg, total cholesterol by 20.28 mg/dL, and weight by 3.91 kg. The reported 95% confidence intervals were minus 1.27 to minus 1.00 percentage points for HbA1c, minus 9.48 to minus 5.79 mmHg for systolic pressure, minus 23.84 to minus 16.73 mg/dL for cholesterol, and minus 4.40 to minus 3.41 kg for weight.[1]
Those are observed clinical changes within this cohort. They should not be read as randomized head-to-head effects. The study was retrospective, and the abstract does not say that participants were randomly assigned among the three treatment groups. Treatment selection, differences present at baseline, changes in other care, missing follow-up data, and other unmeasured factors can affect comparisons in an observational record review.[1] The US label identifies semaglutide products as prescription GLP-1 receptor agonists with specific approved indications. Those label claims are separate from the DIAL2 trajectories studied here.[2] See our semaglutide regulation section for more context.
The high-risk category stayed broadly stable
Standard DIAL2 calculations were available for 329, 327, and 325 participants across the study visits. The proportion in the high category was 24.6% at the first reported visit, 23.2% at the next, and 23.7% at 24 months. The time-by-treatment interaction for this categorical endpoint was not statistically significant, with a p value of 0.731. On this measure, the study did not establish different high-risk trajectories for semaglutide, empagliflozin, and their combination.[1]
The continuous estimate behaved differently. Its time-by-treatment interaction was statistically significant, with a reported p value of 0.002 and a p value of 0.006 after adding demographic-time adjustments. The abstract does not provide every group-specific estimate needed to turn that interaction into a simple ranking. A significant interaction says the modeled trajectories differed over time. It does not, by itself, show that one strategy prevented more cardiovascular events than another.[1]
Chronological age changed the prediction
The complete-case analysis included 324 people. Under the standard calculation, mean predicted one-year risk moved from 2.172% to 2.052%, a relative change of minus 5.5%. In an exploratory calculation that held age fixed, the 24-month estimate was 1.777%, a relative change of minus 18.2%. The gap shows how two additional years of chronological age can offset part of the improvement associated with better risk-factor measurements inside a prediction model.[1]
Holding age fixed is an explanatory exercise, not a second observed outcome. People did age during follow-up. The authors also used exploratory Shapley calculations to examine contributions to the modeled estimate. These decompositions can help explain why a prediction changed, but they cannot identify how many clinical events a treatment caused or prevented.[1] For the broader clinical context, see how semaglutide is studied.
What we do not yet know
This study does not establish that the medicines reduced cardiovascular events during these two years. It also does not establish that the combination was superior to either medicine alone. The authors state both limits directly. The cohort excluded people with prior cardiovascular disease, so the results should not be assumed to describe patients with established disease. The sample was also too small and the design too limited to replace randomized outcome trials.[1]
The paper leaves practical questions open. The abstract does not report treatment discontinuation, adverse events, adherence, changes in other medicines, or detailed baseline differences among groups. It also does not validate a change in DIAL2 score as a treatment target for an individual patient. Prospective work would need prespecified comparisons and observed cardiovascular outcomes to answer the questions that a risk trajectory alone cannot settle.[1]
How to use this result
In this observational cohort, glycaemia, blood pressure, cholesterol, and weight improved while the categorical DIAL2 result remained fairly steady. The continuous prediction shifted, and its interpretation depended partly on whether the calculation allowed age to advance. Repeated risk estimation can describe a cohort, but a modeled probability is not an observed cardiovascular benefit.[1]
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
What did the DIAL-STEP study find?
Several measured risk factors improved over 24 months, while the share classified as high risk by DIAL2 remained close to 24%. The continuous predicted-risk estimate changed over time, but the study did not establish fewer cardiovascular events.
Did semaglutide prevent heart attacks in this study?
The study did not test that outcome. It followed calculated DIAL2 risk trajectories in clinical records rather than counting whether semaglutide prevented heart attacks, strokes, or cardiovascular deaths.
Was this a randomized head-to-head trial?
No. It was a retrospective cohort of people who initiated semaglutide, empagliflozin, or both. Observational comparisons can be affected by baseline differences, treatment selection, missing data, and other care received during follow-up.
Why did holding age fixed change the DIAL2 result?
Age contributes to the risk prediction. The standard calculation allowed participants to age over two years, while an exploratory calculation kept age at baseline. The difference helps explain the model, but it is not a separate clinical outcome.
Sources
- [1]Labate and Villari. Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study (2026; PMID 43003421)Tier 1 · primary↩
- [2]FDA structured product label data for Ozempic and Rybelsus (semaglutide)Tier 1 · primary↩
No revisions yet. First published .